An impairment of barrier size and charge selectivity of glomerular basement membrane in streptozotocin-induced diabetes and prevention by pharmacological therapy.
We examined barrier size (pore size) and charge selectivity (anionic sites) of the glomerular basement membrane (GBM) in experimental diabetes. For estimation of the pore size we employed a new method, tissue negative staining. In diabetic rats, enlarged pores and decreased numbers of anionic sites of GBM were observed. Both insulin treatment and angiotensin-converting enzyme inhibitors prevented these changes. The renoprotective effect of the two drugs is discussed in the article.
Isogai
S
S
Department of Medicine, Yamauchi Hospital, 4-6 Minamifujisawa, Fujisawa, Kanagawa 251-0055, Japan. yoshino@med.toho-u.ac.jp
Mogami
K
K
Ouchi
H
H
Yoshino
G
G
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000838:Anions; D001485:Basement Membrane / Q000187:drug effects / Q000473:pathology*; D002216:Captopril / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology* / Q000503:physiopathology; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008854:Microscopy, Electron; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin
D000806:Angiotensin-Converting Enzyme Inhibitors; D000838:Anions; D013311:Streptozocin; D002216:Captopril